bioRxiv Science⌕ Search

Biology subjects

Pekarskaya, E. A.

Publications and source records attributed to Pekarskaya, E. A..

2 recordsLinked to original sources

Habenular μ-opioid receptor knockout and chronic systemic receptor blockade promote negative affect and heighten nociceptive sensitivity

The -opioid receptor (MOR), a subtype of opioid G protein-coupled receptor, is expressed in multiple brain circuits and is particularly enriched in the habenula, a small epithalamic structure implicated in aversive states. MOR dysfunction has been linked to several psychiatric and nociceptive disorders. Identifying the key brain regions mediating the behavioral consequences of disrupted MOR signaling can shed light on the role of the opioid system in mood and pain regulation. In this study, we administered methocinnamox (MCAM), a long-acting, pseudo-irreversible MOR antagonist, acutely or chronically to adult C57BL/6J mice. A comprehensive behavioral battery was used to assess affective, social, and pain behavior. A single MCAM administration (10 mg/kg, s.c.) did not alter baseline behavior, but blocked opioid-induced analgesia, suggesting that basal {micro}-opioid tone does not contribute to these behaviors. In contrast, chronic MCAM administration (10 mg/kg, s.c., 3x/week for 4 weeks) led to increased anxiety-like behavior and decreased sociability, as well as enhanced mechanical allodynia and thermal hyperalgesia. Remarkably, selective knockout of habenular MORs in adult Oprm1fl/fl mice reproduced key features of the chronic MCAM phenotype, including anxiety-like behavior and mechanical hyperalgesia. Together, these findings reveal that sustained inhibition of MOR signaling disrupts affective and nociceptive processing and highlight the habenula as a node mediating key behavioral deficits of disrupted opioid signaling.

neuroscience↗

Tianeptine, but not fluoxetine, decreases avoidant behavior in a mouse model of early developmental exposure to fluoxetine

Depression and anxiety are two of the most common mental health disorders, often sharing symptoms and administrations. Most pharmacological agents available to treat these disorders target monoamine systems. Currently, finding the most effective treatment for an individual is a process of trial and error. Therefore, to better understand how disease etiology may predict treatment response, we studied mice exposed developmentally to the selective serotonin reuptake inhibitor (SSRI) fluoxetine (FLX). These mice show the murine equivalent of anxiety- and depression-like symptoms in adulthood and here we report that these mice are also behaviorally resistant to the antidepressant-like effects of adult SSRI administration. We investigated whether tianeptine (TIA), which exerts its therapeutic effects through the mu-opioid receptor (MOR) instead of directly targeting monoaminergic systems, would be more effective in this model. We injected C57BL/6J (C57) pups with either FLX (10 mg/kg, i.p) or vehicle from postnatal (PN) day 2 to 11, a period in which mouse brain development parallels that of the third trimester of a human pregnancy. Prior work established that adult 129SvEv (129) mice exposed to FLX in this time period (PN-FLX) showed increased avoidant and decreased hedonic behaviors, which correspond to anxiety- and depressive-like symptoms in humans, respectively. We performed baseline testing in adulthood in C57 PN-FLX animals and confirmed a similar avoidant phenotype to that reported in 129 PN-FLX mice. We then treated these animals with chronic FLX (18 mg/kg in the drinking water) and evaluated effects on two tasks that measure avoidant behavior - the open field and novelty suppressed feeding (NSF) tasks. This administration failed to improve, and even exacerbated, avoidance symptoms in PN-FLX mice. The same animals then underwent chronic administration with TIA (30 mg/kg, 2x/day, i.p.) as an alternative treatment strategy. TIA administration decreased avoidance behavior as measured in the open field and NSF. Overall, this demonstrates that TIA may be a promising alternative treatment to typical antidepressants, especially in patients whose serotonergic system has been altered.

neuroscience↗